Earnings Call Summary | Dare Bioscience(DARE.US) Q1 2024 Earnings Conference
Earnings Call Summary | Dare Bioscience(DARE.US) Q1 2024 Earnings Conference
The following is a summary of the Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript:
以下是达瑞生物科学公司（DARE）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Dare reported Q1 2024 general and administrative expenses of approximately $2.7 million.
R&D expenses were approximately $3.3 million—a 34% decrease compared to Q1 2023.
The Company's loss for the quarter was approximately $6.8 million.
Dare ended the quarter with $3.6 million in cash and equivalents.
Dare secured a non-dilutive strategic royalty financing of $22 million and received total grant funding of approximately $1.8 million.
戴尔报告称，2024年第一季度的一般和管理费用约为270万美元。
研发费用约为330万美元，与2023年第一季度相比下降了34％。
该公司本季度的亏损约为680万美元。
Dare在本季度末获得了360万美元的现金及等价物。
Dare获得了2200万美元的非稀释性战略特许权使用费融资，并获得了总额约180万美元的拨款。
Business Progress:
业务进展：
Dare's product, XACIATO, is now available via prescription nationwide for treating bacterial vaginosis.
The Company is preparing for Phase 3 clinical trials of Sildenafil Cream 3.6% and Ovaprene.
They completed an end-of-Phase 2 meeting with the FDA regarding Sildenafil Cream.
Technological proof-of-concept for DARE-LARC1, Dare's pre-clinical candidate, was announced.
The company continues collaborations with major corporations including Organon for XACIATO and Bayer for Ovaprene.
Dare is planning to initiate a Sildenafil Phase 3 trial in early 2024, hopeful of it being the first Phase 3 study for female sexual arousal disorder.
The company is also progressing with DARE-LARC, a technology similar to 'Nexplanon', and is developing therapies for menopausal vasomotor symptoms and sexual pain.
Dare aims to position women's health at the forefront of innovation.
Dare的产品XACIATO现已在全国范围内通过处方上市，用于治疗细菌性****病。
该公司正在为3.6％的西地那非乳膏和Ovaprene的3期临床试验做准备。
他们完成了与美国食品药品管理局关于西地那非霜的第二阶段末会议。
Dare的临床前候选药物 DARE-LARC1 的技术概念验证已经公布。
该公司继续与包括XACIATO的Organon和Ovaprene的拜耳在内的大公司合作。
Dare计划在2024年初启动西地那非3期试验，希望这是第一项针对女性性唤起障碍的3期研究。
该公司还在开发类似于 “Nexplanon” 的DARE-LARC技术方面取得进展，并且正在开发针对更年期血管舒缩症状和性疼痛的疗法。
Dare旨在将女性健康置于创新的最前沿。
More details: Dare Bioscience IR
更多详情： Dare 生物科学 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。